| Index | S&P 500 | P/E | 24.58 | EPS (ttm) | 13.46 | Insider Own | 14.30% | Shs Outstand | 190.83M | Perf Week | -0.05% |
| Market Cap | 63.13B | Forward P/E | 15.21 | EPS next Y | 21.75 | Insider Trans | -0.02% | Shs Float | 180.25M | Perf Month | 6.80% |
| Enterprise Value | 72.04B | PEG | 1.93 | EPS next Q | 4.58 | Short Float | 2.18% | Perf Quarter | 7.29% | ||
| Income | 2.63B | P/S | 0.19 | EPS this Y | 10.28% | Short Ratio | 3.04 | Perf Half Y | 8.83% | ||
| Sales | 332.77B | P/B | 19.49 | EPS next Y | 10.26% | ROA | 3.13% | Short Interest | 3.93M | Perf YTD | -2.05% |
| Book/sh | 16.97 | P/C | 22.43 | EPS next 5Y | 12.75% | ROE | 106.43% | 52W High | 377.54 -12.37% | Perf Year | -0.70% |
| Cash/sh | 14.75 | P/FCF | 15.55 | EPS past 3/5Y | -0.33% — | ROIC | 12.75% | 52W Low | 244.82 35.14% | Perf 3Y | 74.94% |
| Dividend Est. | 2.40 (0.73%) | EV/EBITDA | 13.99 | Sales past 3/5Y | 10.43% 11.09% | Gross Margin | 3.71% | Volatility | 2.04% 1.95% | Perf 5Y | 168.28% |
| Dividend TTM | 2.40 (0.73%) | EV/Sales | 0.22 | EPS Y/Y TTM | 38.52% | Oper. Margin | 1.30% | ATR (14) | 7.15 | Perf 10Y | 309.76% |
| Dividend Ex-Date | Aug 14, 2026 | Quick Ratio | 0.58 | Sales Y/Y TTM | 5.09% | Profit Margin | 0.79% | RSI (14) | 54.14 | Recom | 2.30 |
| Dividend Gr. 3/5Y | 6.46% 5.77% | Current Ratio | 0.93 | EPS Q/Q | 7.47% | SMA20 | 0.23% | Beta | 0.58 | Target Price | 357.75 |
| Payout | 17.83% | Debt/Eq | 3.62 | Sales Q/Q | 5.07% | SMA50 | 2.31% | Rel Volume | 1.01 | Prev Close | 330.53 |
| Employees | 49,000 | LT Debt/Eq | 3.53 | Earnings | Nov 04 | SMA200 | 4.34% | Avg Volume | 1.31M | Price | 330.84 |
| IPO Date | Apr 04, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.42% -3.37% | Net Debt/EBITDA | 1.73 | Volume | 1,317,141 | Change | 0.09% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Reiterated | Robert W. Baird | $373 → $375 | |
| Oct-20-26 | Reiterated | Argus Research | Buy | $270 → $380 |
| Oct-16-26 | Reiterated | UBS | Buy | $430 → $400 |
| Aug-19-26 | Reiterated | RBC Capital | Sector Perform | $330 |
| Aug-07-26 | Reiterated | Morgan Stanley | Overweight | $342 → $346 |
| Aug-06-26 | Reiterated | Robert W. Baird | $340 → $370 | |
| Aug-06-26 | Reiterated | Evercore ISI Group | Outperform | $360 → $350 |
| Aug-06-26 | Reiterated | UBS | Buy | $412 → $430 |
| Jun-10-26 | Reiterated | Barclays | Overweight | $425 → $350 |
| May-11-26 | Reiterated | Wells Fargo | Overweight | $429 → $331 |
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 332,772 | 321,333 | 293,959 | 262,173 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 320,426 | 311,191 | 285,257 | 254,417 | — | — | — | — | — | |
| Gross Profit | 12,345 | 10,142 | 8,701 | 7,756 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 7,654 | 6,494 | 5,661 | 5,310 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 355 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 4,336 | 3,648 | 3,040 | 2,447 | — | — | — | — | — | |
| Interest Expense | 497 | 420 | 249 | 276 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -231 | -970 | -787 | -10 | — | — | — | — | — | |
| Net Income Before Taxes | 3,607 | 2,258 | 2,004 | 2,161 | — | — | — | — | — | |
| Income Taxes | 968 | 691 | 485 | 428 | — | — | — | — | — | |
| Consolidated Net Income | 2,625 | 1,554 | 1,509 | 1,745 | — | — | — | — | — | |
| Net Income From Continuing Operations | 2,640 | 1,568 | 1,519 | 1,733 | — | — | — | — | — | |
| Net Income | 2,625 | 1,554 | 1,509 | 1,745 | — | — | — | — | — | |
| EPS (Recurring) | 13.52 | 8.02 | 7.60 | 8.62 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 13.52 | 8.02 | 7.60 | 8.62 | — | — | — | — | — | |
| EPS (Diluted) | 13.46 | 7.96 | 7.53 | 8.53 | — | — | — | — | — | |
| EBITDA | 5,148 | 3,747 | 3,371 | 3,417 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 24.58 | 39.26 | 29.89 | 21.10 | — | — | — | — | — | |
| Price To Sales Ratio | 0.19 | 0.19 | 0.15 | 0.14 | — | — | — | — | — | |
| Gross Margin | 3.71 | 3.16 | 2.96 | 2.96 | — | — | — | — | — | |
| Operating Margin | 1.30 | 1.14 | 1.03 | 0.93 | — | — | — | — | — | |
| Net Margin | 0.79 | 0.48 | 0.51 | 0.67 | — | — | — | — | — | |
| Shares Outstanding | 193 | 194 | 199 | 205 | — | — | — | — | — | |
| Market Capitalization | 63,852 | 60,631 | 44,791 | 36,894 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Krikorian Lazarus | SVP & Chief Accounting Officer | Oct 01 '26 | Sale | 303.18 | 986 | 298,935 | 15,183 | Oct 05 |
| GREENBERG LON R | Director | Sep 16 '26 | Sale | 321.30 | 1,280 | 411,264 | 17,128 | Sep 17 |
| Krikorian Lazarus | SVP & Chief Accounting Officer | Sep 01 '26 | Sale | 325.97 | 985 | 321,080 | 16,169 | Sep 02 |
| Campbell Elizabeth S | Executive Vice President | Aug 24 '26 | Sale | 324.12 | 11,300 | 3,662,663 | 19,455 | Aug 25 |
| Tyler Lauren M | Director | Jun 22 '26 | Buy | 270.23 | 550 | 148,627 | 4,359 | Jun 24 |
| DURCAN DERMOT MARK | Director | Jun 18 '26 | Buy | 274.19 | 4,000 | 1,096,760 | 31,767 | Jun 22 |
| DURCAN DERMOT MARK | Director | May 28 '26 | Buy | 266.26 | 4,000 | 1,065,040 | 27,767 | May 28 |
| Cleary James F | Chief Financial Officer | Mar 11 '26 | Option Exercise | 0.00 | 12,623 | 0 | 165,766 | Mar 13 |
| Battaglia Silvana | Executive Vice President | Mar 11 '26 | Option Exercise | 0.00 | 8,415 | 0 | 27,239 | Mar 13 |
| Campbell Elizabeth S | Executive Vice President | Mar 11 '26 | Option Exercise | 0.00 | 12,623 | 0 | 36,548 | Mar 13 |
| Mauch Robert P. | President & CEO | Feb 20 '26 | Sale | 358.94 | 3,762 | 1,350,332 | 65,393 | Feb 24 |
| Mauch Robert P. | President & CEO | Feb 20 '26 | Option Exercise | 86.09 | 3,762 | 323,871 | 69,155 | Feb 24 |
| Mauch Robert P. | President & CEO | Feb 18 '26 | Sale | 359.46 | 1,333 | 479,160 | 65,393 | Feb 20 |
| Mauch Robert P. | President & CEO | Jan 20 '26 | Sale | 354.73 | 5,096 | 1,807,704 | 66,726 | Jan 22 |
| Mauch Robert P. | President & CEO | Jan 20 '26 | Option Exercise | 86.09 | 3,763 | 323,957 | 71,822 | Jan 22 |